



PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 69392

Title: Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview

Reviewer's code: 05186196

Position: Peer Reviewer

Academic degree: MD

Professional title: Academic Research, Attending Doctor, Doctor, Research Fellow

Reviewer's Country/Territory: Romania

Author's Country/Territory: Serbia

Manuscript submission date: 2021-06-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-02 06:34

Reviewer performed review: 2021-07-04 07:00

Review time: 2 Days

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The authors have submitted a well-prepared and interesting narrative review on the possible involvement of galectin-3 in antipsychotic-induced metabolic changes of schizophrenia. The manuscript is well-written and the English language of the paper requires no polishing. The paper is worthy of publication following some minor revisions: 1. I believe the paper can be improved if the authors designed some interesting original Figures and (or) Table to summarize their findings. You can use PowerPoint to prepare some simple figures as it would increase the readability of your paper and attract more readers (and subsequently citations). 2. Chronic comorbidities, e.g., obesity, diabetes, diabetes, hypertension etc., are also characterized by high oxidative stress and low-grade chronic inflammation levels. The authors should acknowledge the fact that patients with schizophrenia most probably have other comorbidities as well and these might also lead to metabolic alterations. If you are interested to read more about the involvement of oxidative stress in diabetes, diabetes, obesity, diabetic dyslipidemia etc, there are some interesting articles previously published in World Journal of Diabetes that you can search for. 3. How are galectin-3 levels influenced by the previously mentioned comorbidities? Or what other factors can influence its levels? Overall, nice work and congratulations! It was a pleasure to read your paper.



PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 69392

Title: Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview

Reviewer's code: 05382439

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Croatia

Author's Country/Territory: Serbia

Manuscript submission date: 2021-06-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-29 10:14

Reviewer performed review: 2021-07-05 10:27

Review time: 6 Days

| | |
|---------------------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Peer-reviewer statements | Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No |



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

A review paper entitled „Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia” aims to further elucidate the potential impact of the glycan Galectin-3 on antipsychotic-induced metabolic changes in schizophrenia. This is a very interesting and nicely written review paper. I consider the topic to be highly important for clinicians and researchers dealing with this serious mental disorder. I only have a few minor suggestions: (1) The authors should consider identifying the manuscript as a review in the title; (2) In the chapter “Galectin-3 and neuro-immuno-metabolic crosstalk” the name of the first author of the reference 57 is misspelled (line 177); (3) Please consider changing “triglyceride” to “triglycerides” (line 183); (4) In my opinion, it would be better to say that antipsychotics might cause weight gain, glucose intolerance and other metabolic complications (lines 198-199).